Prescribing information for lecanemab includes a boxed warning about probable risks connected with ARIA. Correct use recommendations go over techniques to reduce ARIA risk, as does AAN assistance.The extension analyze also evaluated CLARITY AD members who had a delayed begin (those that switched from placebo to lecanemab following the core trial) a